Literature DB >> 19464840

Evaluation of the Abbott ARCHITECT Toxo IgM assay.

Eva Sickinger1, Hans-Bertram Braun, Gerald Praast, Myriam Stieler, Cordelia Gundlach, Claudia Birkenbach, John Prostko, Mary Ann Palafox, Edwin Frias, Stephen Hsu, Matthew Matias, Dominick Pucci, Michael Hausmann, Ulrich Sagel, Darwin Smith.   

Abstract

Development of the ARCHITECT Toxo IgM assay has been done to assist the clinician in acute Toxoplasma gondii infection detection, especially in pregnant women. Its use, in conjunction with ARCHITECT Toxo IgG and Toxo Avidity assays, will provide an array of assays particularly useful in the monitoring of pregnant females to determine the risk of maternal transmission of the parasite. Specificity results from 2 testing sites, using populations of pregnant females, hospital patients, and blood donors, demonstrated that the assay has an overall resolved relative specificity of 99.89% (confidence interval, 99.68-99.98%). Relative specificity for pregnant female specimens was 99.95% (n = 2031). Excellent seroconversion sensitivity was observed for the ARCHITECT Toxo IgM assay, which was similar to the Abbott AxSYM Toxo IgM assay (Abbott Laboratories, Abbott Park, IL). In more than 90% of the panels tested, the 1st bleed detected in the serial bleeds was the same for both assays.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464840     DOI: 10.1016/j.diagmicrobio.2009.03.016

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

2.  Performance characteristics of current-generation Immulite 2000 TORCH Assays.

Authors:  A R Centonze; E Tonolli; R Fontana
Journal:  Clin Vaccine Immunol       Date:  2012-11-21

3.  Chemiluminescent microparticle immunoassay-based detection and prevalence of Toxoplasma gondii infection in childbearing women (Iran).

Authors:  Hossein Sobati
Journal:  J Parasit Dis       Date:  2020-01-01

Review 4.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.